Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 17, 2026
UiPath (PATH) Stock Rises +31.8% Over 30 Days: What’s Fueling the Recovery

UiPath (PATH) Stock Rises +31.8% Over 30 Days: What’s Fueling the Recovery

Key Takeaways

  • PATH shares climbed approximately 31.8% over the 30-day window, from a closing price of $12.15 on July 17, 2026, to $16.01 on August 14, 2026.
  • The advance extends a broader recovery, with the stock up roughly 52% over the trailing three months after touching its 52-week low of $9.20 in mid-May.
  • Improving sentiment around enterprise AI and agentic automation, a constructive analyst target revision, and elevated trading volume supported the move.
  • Fundamentals remain a key anchor: fiscal 2027 first-quarter revenue rose 17.3% year over year to $418.4 million, and management raised its full-year revenue outlook.
  • Wall Street remains measured, with a consensus Hold rating and average 12-month price targets near $13.87, below the latest close.
  • Price swings have been sharp, including a late-July pullback toward $10.20 and an August acceleration above $16.

UiPath (PATH) Company Overview and Market Position

UiPath, Inc. is a global enterprise automation and artificial intelligence software company. Its Business Automation Platform combines robotic process automation with AI-powered capabilities such as document understanding, process mining, test automation, and agentic orchestration tools including Maestro. The company serves large organizations across financial services, healthcare, government, manufacturing, and other industries that use automation to streamline repetitive, complex, and decision-intensive workflows.

UiPath operates primarily through a subscription-based software model and is followed closely by investors as a barometer for enterprise adoption of AI-driven automation. The company has a market capitalization of roughly $8.3 billion and maintains a strong balance sheet, with approximately $1.4 billion in cash and cash equivalents and no outstanding debt as of its latest disclosures. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

UiPath (PATH) Stock Price Performance: Last 30 Days vs. Quarter

Over the most recent 30-day period, PATH moved from a closing price of $12.15 on July 17, 2026, to $16.01 on August 14, 2026. Because 30 calendar days before August 17 falls on a Saturday, the nearest prior trading session close is used. The resulting gain of about 31.8% places the move firmly in price-movement territory.

The path higher was not linear. Shares pulled back sharply in late July, falling from $12.04 on July 21 to $10.20 by July 23, before recovering into month-end. The rally then accelerated in August: the stock rose 8.0% to $14.10 on August 4 and climbed another 9.3% to $16.68 on August 13 on elevated volume, before settling at $16.01 on August 14.

The quarterly trend is even stronger. From a closing price of $10.55 on May 19, 2026, PATH advanced about 51.8% to the latest close. The stock bottomed near $9.20 on an intraday basis in mid-May and has since traded above both its 50-day moving average of roughly $11.97 and its 200-day moving average of roughly $11.50, reflecting a decisive shift in trend.

What Drove PATH Stock Price in the Last 30 Days

The 30-day advance was supported by several verified factors. On August 14, RBC Capital analyst Matthew Hedberg maintained a Sector Perform rating and raised the firm's price target to $15 from $12. The note, which previewed second-quarter results for software names, pointed to more constructive checks and indicated that upside to consensus estimates appeared more likely heading into the second half. The firm also noted that PATH shares had risen about 30% since first-quarter earnings.

Broader investor enthusiasm for AI and agentic automation also played a role. UiPath's positioning in enterprise workflow automation, including agentic orchestration and AI-native case management capabilities, has kept the stock in the center of the AI-software conversation. Institutional ownership remains substantial at approximately 62.5%, and recent regulatory filings showed both accumulation and trimming among large investors as the stock repriced. From what I see, checking signals with Tickeron’s AI Daily Buy/Sell Signals helped put the volume surge in context.

Technically, the breakout above the 50-day and 200-day moving averages attracted momentum-oriented activity, with trading volumes expanding notably during the August advance. At the same time, the rally has moved the stock above the consensus average price target, leaving valuation as a source of debate rather than a catalyst.

What Drove PATH Stock Performance Over the Last Quarter

The three-month recovery traces back to UiPath's fiscal 2027 first-quarter results, reported on May 28, 2026. Revenue of $418.4 million grew 17.3% year over year and exceeded consensus estimates of approximately $397.5 million. Non-GAAP earnings per share came in at $0.15, and management raised its full-year fiscal 2027 revenue guidance to approximately $1.78 billion. Annual recurring revenue reached roughly $1.9 billion, up about 12% year over year.

Those results marked an inflection after a prolonged period of investor skepticism that had pushed the stock toward its 52-week low in mid-May. Since then, product momentum around agentic AI, a strong cash position, and steadier recurring-revenue trends have supported the broader narrative of improving execution. Analyst actions have been mixed but gradually constructive, with targets moving from a tightly clustered $12-to-$15 range into the low-to-mid teens.

PATH Stock Forecast Drivers: What Investors Should Watch Next

The next major catalyst is UiPath's fiscal 2027 second-quarter earnings release and updated guidance. Investors will focus on annual recurring revenue growth, net new ARR, net revenue retention, and whether agentic AI adoption is translating into measurable monetization. Commentary on enterprise software budgets, deal sizes, and public-sector demand will also matter.

Beyond earnings, the stock's relationship to analyst price targets and valuation multiples will remain a key watch item. Macroeconomic conditions, interest-rate expectations, and overall software-sector sentiment could influence momentum, while competition from large platform vendors and changing AI pricing models remain important risk factors. Investors should monitor these developments without treating any single data point as a definitive signal. I’m watching this closely as the next earnings could clarify the sustainability of the recent move.

Using Tickeron’s AI Tools for Deeper Analysis

In my research process, I frequently review Tickeron’s Trending AI Robots page to explore systematic strategies that align with names like PATH. The selection highlights top-performing bots across various risk profiles and holding periods, giving a practical way to compare approaches without relying on any single signal. This helps put price action and volume trends into a broader, data-driven perspective.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PATH

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


PATH in upward trend: price rose above 50-day moving average on July 27, 2026

PATH moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on PATH as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PATH just turned positive on July 29, 2026. Looking at past instances where PATH's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PATH advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 157 cases where PATH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PATH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PATH broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PATH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.359) is normal, around the industry mean (22.961). P/E Ratio (26.683) is within average values for comparable stocks, (74.353). Projected Growth (PEG Ratio) (0.575) is also within normal values, averaging (1.921). PATH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (5.168) is also within normal values, averaging (118.079).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PATH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), MongoDB (NASDAQ:MDB), Twilio (NYSE:TWLO), Zscaler (NASDAQ:ZS), Okta (NASDAQ:OKTA).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.09B. The market cap for tickers in the group ranges from 48.8K to 3.68T. MSFT holds the highest valuation in this group at 3.68T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 3%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 26%. YYAI experienced the highest price growth at 1,349%, while CLBT experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -28% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 72
Price Growth Rating: 55
SMR Rating: 80
Profit Risk Rating: 91
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
PATH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ComputerCommunications

Profile
Details
Industry
N/A
Address
One Vanderbilt Avenue
Phone
+1 844 432-0455
Employees
3024
Web
https://www.uipath.com
Interact to see
Advertisement
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
CME Group delivered record 2025 revenue of $6.52 billion, up 6% year-over-year. Q4 adjusted EPS of $2.77 exceeded expectations.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.